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Letter to the Editor
A SCALE TO ASSESS THE SEVERITY OF LEPROSY REACTIONS
Recognising and assessing the clinical signs and severity of leprosy reactions is essential for diagnosis
and treatment. To promote such awareness there is a potential role for a severity scale that would draw
attention to the early signs of leprosy reactions, the choice of treatment and to changes in response to
treatment. Early work by Naafs & van Droogenbroeck produced a composite measure called the ‘indice
ne´vritique’ (neural index), which used various measures, including motor nerve conduction, an early
type of monofilament sensory testing, voluntary muscle testing and nerve enlargement.1,2 Despite them
demonstrating the utility of this measure, it was not used, possibly because it included
neurophysiological measures, which are frequently not available in centres managing leprosy patients.
Unpublished work by Alison Anderson and others at Green Pastures Hospital & Rehabilitation Centre in
Pokhara, Nepal, explored the potential of another scale to measure reaction severity. The use of a scale
has been reported elsewhere in Nepal.3
Methods
As part of the ILEP Nerve Function Impairment and Reaction (INFIR) Cohort Study,4 we monitored
clinical status and changes in nerve function in advance of Type 1 or Type 2 reactions and undertook a
pilot exercise that assessed 21 items as the basis for a reaction severity scale. These included assessment
of skin signs, fever, oedema and forms of neuritis plus changes in sensory and motor function assessed
using monofilaments (200 mg, 2 g, 4 g, 10 g and 300 g) and voluntary muscle testing (VMT)
respectively. Monofilament assessments at each test point were scored 0 where the 200 mg
monofilament was felt through to 5 where the 300 g monofilament was not felt. Muscle testing was
scored using the standard Medical Research Council (MRC) grading, normal (5), full range of
movement but reduced resistance (4), full range of movement but no resistance (3), movement but
reduced range (2), muscle flicker (1) and paralysed (0).5 For the eye, any gap on strong closure was
substituted for movement but reduced range. Figure 1 summarises test points for hands and feet and the
method of calculation of a severity score ranging from 0 to 70, higher scores being associated with more
severe reactions.
Originally, the scoring of the items in the ‘A-section’ of the severity scale was weighted in such a
way that a score of ‘3’ or more on any individual item would trigger the diagnosis that the outcome event
(reaction or nerve function impairment) was severe and required (steroid) treatment. In the ‘B-section’ a
score of ‘2’ or more triggered the diagnosis ‘severe’.
We used assessments of reaction status at intake from all the 303 cases recruited to the INFIR Cohort
Study to assess scale reliability. Since there were just five individuals diagnosed with Type 2 reactions
the focus here is primarily on Type 1 reactions and recent change in sensory or motor function.
Cronbach’s alpha was used as a measure of internal reliability or consistency of the composite severity
score.6 The value of alpha ranges between 0–1. A value close to 1 indicates high internal agreement of
the different components, i.e., they fit well together. We used Principal Component Analysis (PCA) to
examine clusters of items within the scale that appear to belong together (factors).7 Each factor explains
part of the variability of scores obtained with the scale. Particular sub-scales may be identified in this
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Section A· Score reaction signs and symptoms in the right hand column: 
Scoring: 1 2 3 4 Score
A1 Number of raised and inflamed lesions None 1–3 4–10
A2 
Degree of 
inflammation of skin 
lesions or nodules
None Erythema  or
nodules
Erythema, raised
Plaques or nodules Ulceration 
A3 Peripheral oedemadue to reaction None Minimal
Visible, but not 
affecting function 
Oedema
affecting 
function 
A4 Fever due to reaction <37·5 37·6–38·9 
A5 
Involvement of other
organs 
(eye, testes etc)
None Mild Definite
A6 Nerve pain and/orparaesthesia None 
Intermittently,
not limiting 
activity 
Sleep disturbed 
and/or activity 
diminished 
Incapacitating 
A7 Nerve tenderness ongentle palpation None 
Absent if
attention is 
distracted 
Present if
attention is 
distracted 
Withdraws limb
forcibly 
Section B· Score sensory assessments in the right hand column: 
Scoring: 1 2 3 Score
B1 Ulnar – left No recent worsening 1 to 2 points worse
3 to 8
points worse
9 to 16 points 
worse 
B2 Ulnar – right No recent worsening 1 to 2 points worse
3 to 8
points worse
9 to 16 points 
worse 
B3 Median – left No recent worsening 1 to 2 points worse
3 to 8
points worse
9 to 16 points 
worse 
B4 Median – right No recent worsening 1 to 2 points worse
3 to 8
points worse
9 to 16 points 
worse 
B5 Pos· Tib· left No recent worsening 1 to 2 points worse
3 to 8
points worse
9 to 16 points 
worse 
B6 Pos· Tib right No recent worsening 1 to 2 points worse
3 to 8
points worse
9 to 16 points 
worse 
Section C - Score motor assessments in the right hand column: 
Scoring: 1 2 3 Score
C1 Facial – left No recent worsening 1 point worse 2 points worse 3 to 5 points 
worse 
C2 Facial – right No recent worsening 1 point worse 2 points worse 3 to 5 points 
worse 
C3 Ulnar – left No recent worsening 1 point worse  2 points worse 3 to 5 points 
worse 
C4 Ulnar – right No recent worsening 1 point worse  2 points worse 3 to 5 points 
worse 
C5 Median – left No recent worsening 1 point worse 2 points worse 3 to 5 points 
worse 
C6 Median – right No recent worsening 1 point worse 2 points worse 3 to 5 points 
worse 
C7 Lat· Pop· – right No recent worsening 1 point worse 2 points worse 3 to 5 points 
worse 
C8 Lat· Pop· – left No recent worsening 1 point worse 2 points worse 3 to 5 points 
worse 
Total score, sections A + B + C: 
0
0
0
Reaction Severity Assessment 
39 
>10
Figure 1. Severity Scale coding and data collection.
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way (principal components). Analysis of variance was used to compare severity score means between
groups. Formal validation of a scale requires that scores be compared with an independent clinical
assessment of severity. Since the INFIR Cohort Study entailed some 3 hours of neurological and other
assessments at each follow-up visit we were unable to complete this additional assessment. However, an
independent but retrospective assessment of clinical records identified 85 individuals with severe
reactions, 30 with moderate reactions and 43 with mild reactions at intake.
Results
Our analysis gave a value for Cronbach’s alpha of 0.77, indicating good agreement between items. PCA
identified a main factor accounting for 45% of total variance and a second factor explaining an
additional 26% of the variation. Figure 2 compares the severity scores between the ‘severity groups’
identified by assessment of clinical records.
The mean severity score for individuals with no reaction was 0.88 (standard deviation 1.18), mild
reactions 0.86 (sd 1.14), moderate reactions 4.1 (sd 2.90) and severe reactions 8.5 (sd 4.91). We found
statistically significant differences in severity scores between groups but failed to differentiate between
the groups with mild and no reaction.
Discussion
Our findings suggest that, subject to formal validation and reliability testing, a reaction severity score
may play an important role in informing clinical decisions about reactions, the choice of treatment and
monitoring progress. However, our findings raise issues concerning the choice and scoring of scale
items and the relative importance of symptoms.
First, are there additional items or alternative forms of scoring that would make the scale more
sensitive to differences in severity, specifically in relation to mild forms of reaction? Or does the current
scale reflect reality, namely that there is not enough difference between a state of ‘no reaction’ and a
‘mild reaction’ to be worth detecting with a severity scale? Conversely, is there duplication in the listed
items that produces a bias towards severe reactions? Further analysis of our data failed to identify such
items or weightings.
Figure 2. Mean, inter-quartile range, minimum and maximum of severity scores within groups independently
assessed for reaction severity in the INFIR Cohort Study, Uttar Pradesh, India (n ¼ 303).
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The second point focuses on the relative importance of symptoms. While a value of 0.77 for
Cronbach’s alpha suggests good agreement between items, we noted that principal components analysis
identified an additional independent factor (dimension) in the data that contrasted items describing skin
signs with those describing sensory and motor function. This dimension accounted for 26% of the total
variation and suggests that, while the combined items provide an adequate general measure of severity,
there is a distinction between signs related to nerve function and other signs of reaction. This may be
important in the light of the fact that some reactions manifest with skin and nerve involvement, while
other reactions show only skin or only nerve involvement. Our coding system gave approximately equal
weight to skin involvement and recent changes in nerve function. Does this reflect the relative clinical
importance of these two groups of items? Given the longer-term implications of nerve impairment, is
there a case for giving additional weight to items reflecting recent change in nerve function? Would this
make the scale less sensitive to visible symptoms of reaction that may be the primary concern of the
affected person?
We invite correspondence on these issues. Further (field)work on a severity scale for Type 1
reactions has started in 2006. There is also a separate research programme concerned with assessing the
severity of Type 2 reactions.
None of the authors were involved in the editorial process for this letter, which was edited by
Prof. Anthony Bryceson.
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